Track UCB SA — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

UCB SA UCBJY · Stock Open UCB SA in new tab

163.75 USD
P/E
25.06
EPS
6.60
Yield
0.50%
Safety Score
92
P/B
4.82
ROE
20.57
Beta
0.11
Target Price
178.77 USD
UCB SA logo

UCB SA

🧾 Earnings Recap – Q2 2026

Shares dropped 10.1% following earnings, reflecting investor disappointment likely tied to cautious outlook signals despite management’s upbeat commentary on growth and pipeline progress.

  • Net sales growth of over 28% at constant rates driven by five key products representing more than 50% of revenue.
  • Management highlighted multiple clinical wins, including BIMZELX demonstrating superiority in psoriatic arthritis and ongoing lifecycle extensions.
  • Pipeline advancement includes moving bepranemab into a confirmatory Phase II study despite a missed primary endpoint, indicating some developmental risks.
  • Four strategic acquisitions completed, expanding capabilities in cell therapy and T-cell engagers, aiming to bolster long-term growth.
  • Despite management’s positive tone on growth and innovation, the significant share decline suggests underlying investor concerns about sustainability or the long-term outlook.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E25.06
EPS6.60
Book Value34.33
Price to Book4.82
Debt/Equity30.79
Growth
Revenue Growth0.23%
Earnings Growth1.35%
Estimates
Forward P/E18.94
Forward EPS8.73
Target Mean Price178.77
Dividend
Dividend Yield0.50%
Annual dividends0.73 USD
Ex-Div. DateMay 5, 2026
Payout12.58%
5y avg Yield1.21%

DCF valuation

Model fair value for UCB SA (UCBJY)
Result
Sign in to run the valuation for UCBJY.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus Strong buy · mean target 178.77 USD (low 172.32, high 185.21) · as of 10 Nov 2026
Low 172.32
Mean 178.77
High 185.21
Price 163.75
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

UCB SA Logo UCB SA Analysis (UCBJY)

Belgium Health Care Official Website Stock

Is UCB SA a good investment? UCB SA (UCBJY) is currently trading at 163.75 USD. Market analysts have a consensus price target of 178.77 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 25.06. This valuation is generally in line with the broader market.

Earnings Schedule: UCB SA is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 8.73.

For income investors, UCB SA pays a dividend yield of 0.50%. With a payout ratio of 13%, the dividend appears sustainable.

Investor FAQ

Does UCB SA pay a dividend?

Yes, it pays an annual dividend of 0.73 USD (0.50% yield).

What asset class is UCB SA?

UCB SA is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 6.60.

Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Exchange Ticker
FRA (Germany) UNC0.F
PNK (United States) UCBJY
Trades
Dividend Yield
0.50%
5y avg 1.21%
Annual Dividends
0.73USD
Next Ex. Div Date
May 5, 2026
Payout Ratio
12.58%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
0.87 USD
May 18, 2027 (estimated) 0.8685
▸2026
0.85 USD
May 26, 2026 0.8490
▸2025
0.79 USD
May 14, 2025 0.7900
▸2024
0.73 USD
May 15, 2024 0.7250
▸2023
0.73 USD
May 18, 2023 0.7320
▸2022
0.70 USD
May 18, 2022 0.7020
▸2021
0.76 USD
May 19, 2021 0.7626
▸2020
0.67 USD
May 21, 2020 0.6700
▸2019
0.68 USD
May 15, 2019 0.6766
▸2018
0.70 USD
May 17, 2018 0.7035
▸2017
0.63 USD
May 18, 2017 0.6275
▸2016
0.63 USD
May 18, 2016 0.6334
▸2015
0.59 USD
May 21, 2015 0.5938
▸2014
0.72 USD
May 20, 2014 0.7180
▸2013
0.67 USD
May 22, 2013 0.6676
▸2012
0.65 USD
May 18, 2012 0.6542
▸2011
0.70 USD
May 20, 2011 0.6995
▸2010
0.60 USD
May 21, 2010 0.6048
Upcoming Dividends
Name Payment Date Status Amount
UCB SA May 26, 2026 0.849 USD
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion